MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.995
-0.035
-0.87%
After Hours: 4.030 +0.035 +0.88% 16:34 09/19 EDT
OPEN
4.060
PREV CLOSE
4.030
HIGH
4.060
LOW
3.970
VOLUME
38.63K
TURNOVER
--
52 WEEK HIGH
4.500
52 WEEK LOW
2.920
MARKET CAP
90.09M
P/E (TTM)
-4.5434
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BCLI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BCLI News

  • Is Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Growing Too Fast?
  • Simply Wall St..11h ago
  • BrainStorm Names Preetam Shah, Ph.D., M.B.A., as CFO
  • Benzinga.09/09 07:42
  • BrainStorm Strengthens Senior Executive Management Team with the Appointment of Preetam Shah, Ph.D., M.B.A., as Chief Financial Officer
  • GlobeNewswire.09/09 06:00
  • BrainStorm Cell Therapeutics to Present Late Breaking News ePoster at the 35th ECTRIMS Congress on Friday September 13
  • Benzinga.09/06 08:40

More

Industry

Biotechnology & Medical Research
+0.01%
Pharmaceuticals & Medical Research
+0.41%

Hot Stocks

Name
Price
%Change

About BCLI

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More

Webull offers Brainstorm Cell Therapeutics Inc (BCLI) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.